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Association of GestationalWeight Gain
With AdverseMaternal and Infant Outcomes
LifeCycle Project-Maternal Obesity and Childhood Outcomes Study Group
IMPORTANCE Both low and high gestational weight gain have been associated with adverse
maternal and infant outcomes, but optimal gestational weight gain remains uncertain and not
well defined for all prepregnancy weight ranges.
OBJECTIVES To examine the association of ranges of gestational weight gain with risk of
adverse maternal and infant outcomes and estimate optimal gestational weight gain ranges
across prepregnancy bodymass index categories.
DESIGN, SETTING, AND PARTICIPANTS Individual participant-level meta-analysis using data
from 196670 participants within 25 cohort studies from Europe and North America (main
study sample). Optimal gestational weight gain ranges were estimated for each prepregnancy
bodymass index (BMI) category by selecting the range of gestational weight gain that was
associated with lower risk for any adverse outcome. Individual participant-level data from
3505 participants within 4 separate hospital-based cohorts were used as a validation sample.
Data were collected between 1989 and 2015. The final date of follow-up was December 2015.
EXPOSURES Gestational weight gain.
MAIN OUTCOMES ANDMEASURES Themain outcome termed any adverse outcomewas
defined as the presence of 1 or more of the following outcomes: preeclampsia, gestational
hypertension, gestational diabetes, cesarean delivery, preterm birth, and small or large size
for gestational age at birth.
RESULTS Of the 196670women (median age, 30.0 years [quartile 1 and 3, 27.0 and
33.0 years] and 40937 were white) included in themain sample, 7809 (4.0%) were
categorized at baseline as underweight (BMI <18.5); 133 788 (68.0%), normal weight
(BMI, 18.5-24.9); 38 828 (19.7%), overweight (BMI, 25.0-29.9); 11 992 (6.1%), obesity
grade 1 (BMI, 30.0-34.9); 3284 (1.7%), obesity grade 2 (BMI, 35.0-39.9); and 969 (0.5%),
obesity grade 3 (BMI,40.0). Overall, any adverse outcome occurred in 37.2% (n = 73 161)
of women, ranging from 34.7% (2706 of 7809) among women categorized as underweight
to 61.1% (592 of 969) among women categorized as obesity grade 3. Optimal gestational
weight gain ranges were 14.0 kg to less than 16.0 kg for women categorized as underweight;
10.0 kg to less than 18.0 kg for normal weight; 2.0 kg to less than 16.0 kg for overweight;
2.0 kg to less than 6.0 kg for obesity grade 1; weight loss or gain of 0 kg to less than 4.0 kg
for obesity grade 2; and weight gain of 0 kg to less than 6.0 kg for obesity grade 3. These
gestational weight gain ranges were associated with low tomoderate discrimination between
those with and those without adverse outcomes (range for area under the receiver operating
characteristic curve, 0.55-0.76). Results for discriminative performance in the validation
sample were similar to the corresponding results in themain study sample (range for area
under the receiver operating characteristic curve, 0.51-0.79).
CONCLUSIONS AND RELEVANCE In this meta-analysis of pooled individual participant data
from 25 cohort studies, the risk for adverse maternal and infant outcomes varied by
gestational weight gain and across the range of prepregnancy weights. The estimates of
optimal gestational weight gain may inform prenatal counseling; however, the optimal
gestational weight gain ranges had limited predictive value for the outcomes assessed.
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G estational weight gain has been found to be related tothe riskofpregnancycomplications,maternalpostpar-tumweight retention, and obesity in offspring.1-3 Ges-
tational weight gain reflects multiple characteristics, includ-
ingmaternal fat accumulation, fluidexpansion,andthegrowth
of the fetus, placenta, and uterus.4 Gestational weight gain is
necessary to ensure a healthy fetus, but excessive gestational
weight gain has been associated with adverse outcomes.
Higherprepregnancybodymass index (BMI; calculatedas
weight in kilogramsdividedbyheight inmeters squared) also
hasbeenassociatedwith lower gestationalweight gain and in-
creased risk for adversematernal and infant outcomes. There-
fore, optimal gestational weight gain ranges should account
for prepregnancy BMI.5,6 Existing guidelines for gestational
weight gain fromtheUSNationalAcademyofMedicine (NAM;
formerly the InstituteofMedicine)have limitations suchas the
reliance on a limited number of observational studies relat-
ing gestational weight gain to 5 maternal and offspring out-
comes and insufficient information about important preg-
nancyoutcomes (eg, gestational hypertensionandgestational
diabetes).7 In addition, theNAMguidelinesdonot include rec-
ommendations for obesity grade 1, 2, and 3 separately even
thoughtheprevalenceofextremeobesity is increasing inWest-
ern populations. Information regarding optimal gestational
weight gain across a range of maternal BMI categories is im-
portant for the identification of groups at increased risk.
This studypooled individualparticipantdata from25preg-
nancyandbirth cohorts fromEuropeandNorthAmerica to as-
sess associationsof theamountof gestationalweightgainwith
maternaland infantoutcomesaccording tobaselineweight sta-
tusofunderweight,normalweight,overweight,obesitygrade1,
obesity grade 2, and obesity grade 3.
Methods
Inclusion Criteria and Participating Cohorts
This study was part of an international LifeCycle Project col-
laboration on maternal obesity and childhood outcomes.8,9
A pregnancy or birth cohort study was eligible for inclusion if
it includedmotherswithsingleton live-bornchildrenwhowere
born between 1989 and 2015, had information on maternal
prepregnancy or early-pregnancy BMI, and had at least 1 off-
spring measurement (birth weight or childhood BMI). The
finaldateof follow-upwasDecember2015.Noexclusionswere
made based on previous pregnancy or birth complications.
The cohorts included had received institutional review
board approval and written informed consent had been ob-
tained. We invited 50 Western cohorts from Europe, North
America, andOceania thathadbeenselected fromexistingcol-
laborations on childhood health (the EarlyNutrition Project,
the CHICOS Project, and Birthcohorts.net, which was ac-
cessed until July 2014), of which 39 cohorts agreed to partici-
pate.Onlyparticipantswith informationonmaternal prepreg-
nancy BMI, gestational weight gain, and at least 1maternal or
infant outcome of interest were included.
Ofthe29cohortswiththerequireddata,25werepopulation-
based cohorts and were included in the main study sample.
Theremaining4hospital-basedcohortswere includedastheex-
ternal validation sample (eFigure 1 in theSupplement). The in-
cludedcohortsandthedatacollectionmethodsappearineTable1
the Supplement.Women could be includedmore than once in
the analyses if theyhadmultiple singletonpregnancies during
the studyperiod.Anonymizeddata setswere storedonasingle
central secure data server thatwas only accessible by themain
investigator analysts (E.V. andR.G.).
Maternal Prepregnancy BMI and GestationalWeight Gain
Maternal prepregnancy BMI was grouped into categories by
2 BMI units and clinical BMI groups according toWorldHealth
Organizationdefinitions.10Dataontotalgestationalweightgain
in kilograms,whichwasdefined as thedifference between the
latestweightbeforedeliveryandtheprepregnancyweight,were
provided by the cohorts. Gestational weight gainwas grouped
into categories of 2 kg each, ranging fromweight loss toweight
gainof28kgorgreater.Smaller incrementsofgestationalweight
gain were not used because of insufficient statistical power
among underweight and severely obesewomen. Categories at
theextremesofgestationalweightgainwerecombined forma-
ternal underweight, obesity grade2, andobesity grade3.Tobe
included, women were required to have data for maternal
prepregnancyBMI,totalgestationalweightgain,andanyadverse
outcome (defined below).
AdverseMaternal and Infant Outcomes
Themainoutcomeoftheanalyseswasthecompositeanyadverse
outcome,whichwas defined as the presence of at least 1 of the
followingoutcomes:preeclampsia,gestationalhypertension,ges-
tationaldiabetes, cesareandelivery,pretermbirth, andsmall or
large size for gestational age at birth. Pretermbirthwasdefined
as gestational age at birth of less than 37weeks. Sex- and gesta-
tional age–adjusted SD scores for birth weight were calculated
usingaNorthernEuropeanreferencechart.11Smallandlargesizes
for gestational age at birthwere defined as sex- and gestational
age–adjustedbirthweightlessthanthe10thpercentileandgreater
than the 90th percentile, respectively,within each cohort.
For the sensitivity analyses, sex- and age-adjusted SD
scores were calculated for childhood BMI based on reference
growthcharts fromtheWorldHealthOrganization.12,13 TheSD
Key Points
Question What is the associationof gestationalweight gain (across a
rangeof prepregnancyweights)withmaternal and infant outcomes?
Findings In thismeta-analysis of individual participantdata from25
pooledcohortstudiesand196670participants,prepregnancyweight
and themagnitude of gestational weight gainwere associatedwith
risk for any adverse outcome (defined as1 of the following:
preeclampsia, gestational hypertension, gestational diabetes,
cesareandelivery,pretermbirth,andsmallor largesize forgestational
ageatbirth); however, themagnitudeof gestationalweight gainwas
weakly associatedwith the adverse outcomes assessed.
Meaning These findings may inform prenatal counseling
regarding optimal weight gain during pregnancy; however, the
magnitude of gestational weight gain was weakly associated with
the outcomes assessed.
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scores were obtained using data from the highest age avail-
able for each child (median age, 84.9 months [quartile 1 and
3,61.9and95.9months]) andcategorizedasunderweight,nor-
mal weight, and overweight or obesity (referred to as over-
weight) using World Health Organization cutoffs.12,13
Statistical Analysis
Exploratorymultilevel linear regressionmodelswere used to
assess associations of maternal baseline characteristics with
total gestational weight gain. The absolute risk for any ad-
verse outcome was estimated across the full range of mater-
nal prepregnancy BMI and gestational weight gain. Absolute
riskswere calculatedas thepercentageofwomenwithanyad-
verse outcome within each combination of BMI and gesta-
tionalweightgain categories. Similarly, theabsolute riskswere
estimated foranyadverseoutcomeandforeach individualout-
come across the range of gestational weight gain categories
within each clinical BMI group.
Theoptimalgestationalweightgain rangesper clinicalBMI
groupwere constructed. The odds ratios (ORs) for any adverse
outcomewere calculated for each gestational weight gain cat-
egorywithintheparticularclinicalBMIgroupvsallotherwomen
within that BMI group. The individual-level data from all co-
horts were analyzed simultaneously using multilevel models.
Themodels followed a 2-level hierarchical structurewith par-
ticipants (level 1)nestedwithincohorts (level2).Weusedagen-
eralized linearmixedmodelwith a binominal distribution and
logit link. A random intercept at the cohort level was included
to allowvariation in thebaseline risk for each cohort. Allowing
a randomslope for gestationalweight gaindidnot improve the
models. Model assumptions regarding linearity, independent
errors, and influential values were met. Optimal gestational
weightgainwasdefinedasallweightgaincategorieswithasta-
tistically significant protective association (OR <1) for any ad-
verse outcome.14 If a gestational weight gain category with a
nonsignificant association was between 2 significant esti-
mates with an OR of less than 1, that category was included in
the optimal gestational weight gain range. To construct easily
interpretableoptimalgestationalweightgainrangesdirectlyap-
plicable for clinical practice, the main analyses were not ad-
justed formaternal age or parity.We also assessed continuous
associations of maternal prepregnancy BMI and total gesta-
tional weight gain in SDs with any adverse outcome and com-
pared the strengthof these associations byusingZ tests for the
difference in ORs.
The following sensitivity analyses were performed: (1) we
redefined the gestational weight gain ranges based on protec-
tive associations only (OR <1) regardless of statistical signifi-
cance; (2) we adjusted the models for gestational age at birth
and excluded preterm births because gestational weight gain
depends on length of gestation; (3) we excluded participants
withmissingdataonseparateadversematernal and infantout-
comes; (4) we adjusted for maternal age and parity to explore
whether optimal gestationalweight gain rangeswould change
whenmaternal age and parity were taken into account; (5) we
excluded cesarean delivery as an adverse outcome and in-
cludedchildhoodunderweight andoverweight as adverseout-
comestoexplorewhetheroptimalgestationalweightgainranges
wouldchangedependingonthedefinitionof thecompositeout-
come; and (6) we excluded preeclampsia and gestational dia-
betesasoutcomestoaddresspossiblereversecausation.Wealso
constructed optimal gestationalweight gain ranges during the
firsthalfofpregnancy,whichweredefinedas thedifferencebe-
tweenweight atmedian gestational age of 15.4weeks (quartile
1 and 3, 13.2 and 17.1 weeks) and prepregnancy weight using
a similar approach.
The clinical performance of the gestational weight gain
ranges in this studywere assessed as secondary analyses and
compared with the NAM guidelines by assessing the number
of participants classified as having inadequate or excessive
weight gain, the associationswith adverse outcomesusingbi-
nary logistic multilevel models, and the discriminative per-
formance for both classification systems. The discriminative
performance of the classification (the ability of the classifica-
tion todiscriminatebetween thosewithand thosewithout the
outcome) from this study and the NAM guidelines was as-
sessed based on the area under the receiver operating charac-
teristic curve (AUROC).15 Predicted probabilities were ob-
tained from binary logistic multilevel models assessing the
associations of inadequate and excessive gestational weight
gainwith theoutcomes.Thepredictedprobabilitieswereused
to calculate the AUROC. To assess the associations of the op-
timal gestational weight gain ranges with clinically relevant
outcomes not used for the construction of the ranges,we also
assessed low and high birth weight (≤2500 g or ≥4000 g). In
addition, the clinical performance of both classification sys-
temswasassessed in theexternalvalidationsample (n = 3505).
All statistical testswere2-sidedwitha significance thresh-
old of .05. However, the secondary analyses were not ad-
justed formultiple testing; therefore, these findings shouldbe
considered exploratory. All statistical analyses were per-
formed using SPSS Statistics version 24.0 (IBM) and R ver-
sion 3.3.3 (R Foundation for Statistical Computing).
Results
Participant Characteristics inMain Sample
Of the 29 cohorts with the required data (n = 200 175 partici-
pants), 25 were population-based cohorts (n = 196670wom-
en) andwere included as themain study sample (median age,
30.0 years [quartile 1 and 3, 27.0 and 33.0 years] and 40937
were white). At baseline, 7809 women (4.0%) were catego-
rized as underweight (BMI <18.5); 133 788 (68.0%), normal
weight (BMI, 18.5-24.9); 38828 (19.7%),overweight (BMI,25.0-
29.9); 11 992 (6.1%), obesity grade 1 (BMI, 30.0-34.9); 3284
(1.7%), obesity grade 2 (BMI, 35.0-39.9); and 969 (0.5%), obe-
sity grade 3 (BMI, ≥40.0) (Table). Overall, any adverse out-
come occurred in 37.2% (n = 73 161) of women, ranging from
34.7% (2706 of 7809) among women categorized as under-
weight to61.1%(592of969)amongwomencategorizedasobe-
sity grade 3.
Womenwho gainedmore gestational weight had a lower
maternal prepregnancy BMI and were slightly younger and
more often nulliparous than multiparous (eTable 2 in the
Supplement). There were no missing data for any individual
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adverse outcome for 169437 women (86.2%). Of the remain-
der, 17093women (8.7%)weremissingdata for gestationalhy-
pertensive disorders (including preeclampsia and gestational
hypertension), 6898 (3.5%) for gestational diabetes, 9786
(5.0%) for cesareandelivery,8541 (4.3%) forpretermbirth, and
6453 (3.3%) for size (small or large) for gestational age at birth
(eTable 3 in the Supplement). Based on the profiles of all in-
cluded cohorts, the percentage ofwomen includedwithmul-
tiple singleton pregnancies is about 1%.
Participant Characteristics in Validation Sample
Therewere3505womenincludedinthevalidationsample.They
had a median age of 31.0 years (quartile 1 and 3, 27.7 and 34.7
years) and 1696werewhite.Therewere277women (7.9%) cat-
egorized as underweight; 2400 (68.5%), normal weight; 577
(16.5%),overweight; 188 (5.4%),obesitygrade 1; 53 (1.5%), obe-
sitygrade2;and10(0.3%),obesitygrade3.Anyadverseoutcome
occurred in 1423women (40.6%; eTable 4 in the Supplement).
Therewerenomissingdata for any individual adverseout-
come for 3059women (87.3%). Of the remainder, 423women
(12.1%) were missing data for gestational hypertensive disor-
ders (including preeclampsia and gestational hypertension),
421 (12.0%) for gestational diabetes, 15 (0.4%) for cesareande-
livery,426 (12.2%) forpretermbirth,and7 (0.2%) for size (small
or large) for gestational age at birth (eTable 3 in the Supple-
ment). eTables 5 and 6 in the Supplement provide cohort-
specific information for both themain sample and the valida-
tion sample.
Maternal Prepregnancy BMI, GestationalWeight Gain,
and Absolute Risk for Any Adverse Outcome
Theabsolute risk for anyadverseoutcome increasedacross the
full range of maternal prepregnancy BMI and was largely in-
dependentof gestationalweight gain (Figure 1). The lowest ab-
solute riskswere observed amongwomenwith low tonormal
BMI and amoderate to high total gestationalweight gain. The
lowest riskwas 26.7% (16 of 60) for womenwith a BMI of less
than 18.0andgestationalweight gainof 26.0kg to27.9kg.The
highestabsoluteriskswereobservedamongwomenwithahigh
BMI and a high gestational weight gain. The highest risk was
94.4% (17 of 18) for womenwith a BMI of 40.0 or greater and
gestational weight gain of 20.0 kg to 21.9 kg.
Amongwomen categorized as underweight, the absolute
risk for any adverse outcome ranged from29.2% (387 of 1326)
for gestational weight gain of 14.0 kg to 15.9 kg to 50.2% (203
of404) forgestationalweightgainof less than8.0kg (Figure2).
Of all outcomes separately, the absolute risk was highest for
small size for gestational age (highest risk: 32.1% [125 of 390]
for gestational weight gain <8 kg).
Among women categorized as normal weight, the abso-
lute risk for any adverse outcome ranged from 31.7% (7314 of
23073) forgestationalweightgainof 14.0kg to 15.9kg to46.9%
(1256of 2679) for gestationalweight gain of 28.0 kg or greater
and was highest at both extremes of gestational weight gain.
Amongwomencategorizedasoverweight, theabsoluterisk
for anyadverseoutcome increased from37.3% (249of667) for
gestationalweightgainof2.0kg to3.9kg to56.4%(624of 1107)
Figure 1. Heatmap of Absolute Risk for Any AdverseMaternal or Infant Outcome
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Values represent the absolute risks of any adversematernal and infant outcome
(left panel) and the percentages of participants (right panel) for each combination
of bodymass index and gestational weight gain. Absolute riskwas calculated as
No. of participants (any adverse outcome)/No. of participants (bodymass index
and gestational weight gain category) × 100. The percentages of participantswere
calculated as the number of participantswith each combination of bodymass
index and gestational weight gain as a percentage of the total study sample.
The total study sample sizewas 196670. Participants in the extreme categories of
prepregnancy bodymass index (calculated asweight in kilograms divided by
height inmeters squared) and gestational weight gain had values beyond themost
extreme labeled tickmarks. Any adverse outcome includes preeclampsia
(gestational hypertension plus proteinuria), gestational hypertension (systolic
blood pressure140mmHg, diastolic blood pressure90mmHg, or both after
20weeks of gestation in previously normotensivewomen), gestational diabetes
(a randomglucose level >11.0mmol/L, a fasting glucose level7.0mmol/L,
or a fasting glucose level between6.1 and6.9mmol/Lwith a subsequent abnormal
glucose tolerance test [glucose level >7.8mmol/L after glucose intake]), cesarean
delivery, pretermbirth (gestational age at birth <37weeks), and small or large size
for gestational age at birth (sex- and gestational age–adjusted birthweight <10th
percentile and >90th percentile, respectively).
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for gestational weight gain of 28.0 kg or greater. Of all out-
comes separately, the absolute risk was highest for cesarean
delivery (highest risk:25.1%[272of 1084] forgestationalweight
gain of ≥28.0 kg).
Among women categorized as obesity grade 1, 2, or 3, the
absoluteriskforanyadverseoutcomeincreasedacrosstherange
ofgestationalweightgain.Thehighestabsoluteriskswere63.7%
(160 of 251) for gestational weight gain of 28.0 kg or greater in
Figure 2. Absolute Risk for AdverseMaternal or Infant Outcomes
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Absolute riskwas calculated as (No. of womenwith adverse outcome/No. of
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The symbols represent the absolute risk for women in each gestational weight
gain category. The gestational weight gain categories were 2 kg each. Participants
in the extreme categories of gestational weight gain had values beyond themost
extreme labeled tickmarks. Thematernal bodymass index (calculated asweight
in kilograms divided by height inmeters squared) categories were underweight
(<18.5), normal weight (18.5-24.9), overweight (25.0-29.9), obesity grade 1
(30.0-34.9), obesity grade 2 (35.0-39.9), and obesity grade 3 (40.0). Any
adverse outcome includes preeclampsia (gestational hypertension plus
proteinuria), gestational hypertension (systolic blood pressure140mmHg,
diastolic blood pressure90mmHg, or both after 20weeks of gestation in
previously normotensivewomen), gestational diabetes (a randomglucose level
>11.0mmol/L, a fasting glucose level7.0mmol/L, or a fasting glucose level
between 6.1 and 6.9mmol/Lwith a subsequent abnormal glucose tolerance test
[glucose level >7.8mmol/L after glucose intake]), cesarean delivery, preterm birth
(gestational age at birth <37weeks), and small or large size for gestational age at
birth (sex- and gestational age–adjusted birthweight <10th percentile and >90th
percentile, respectively). The odds ratios for the risk of any adverse outcome
were 1.28 (95%CI, 1.27-1.29) and 1.04 (95%CI, 1.03-1.05) per 1-SD increase in
maternal prepregnancy bodymass index and gestational weight gain,
respectively (P < .001 for comparison). The number of cases for each outcome
and the total number of participants in each gestational weight gain category
appears in eTable 7 in the Supplement.
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womencategorizedasobesitygrade1,67.7%(384of567) forges-
tationalweight gain of 16.0 kg or greater inwomen categorized
as obesity grade 2, and 78.8% (93 of 118) for gestational weight
gainof16.0kgorgreater inwomencategorizedasobesitygrade3.
TheassociationofmaternalprepregnancyBMIwith the risk for
anyadverseoutcomeswasstronger than theassociationofges-
tational weight gain. The ORs for the risk of any adverse out-
comewere 1.28 (95%CI, 1.27-1.29) and 1.04 (95%CI, 1.03-1.05)
per 1-SD increase in maternal prepregnancy BMI and gesta-
tionalweightgain, respectively (P<.001forcomparison).Theab-
solute data for each gestational weight gain category appear in
eTable 7 in the Supplement.
Optimal GestationalWeight Gain per Clinical BMI Group
Theoptimal gestationalweightgain rangesassociatedwith the
lowest risks foranyadverseoutcomeappear inFigure3.Among
women categorized as underweight, the optimal gestational
weight gain range was 14.0 kg to less than 16.0 kg, with cor-
respondingORandabsolute risk reduction (ARR; thepercent-
age reduction in absolute risk of any adverse outcome) of0.74
(95% CI, 0.65-0.84) and 0.07% (95% CI, 0.04%-0.09%), re-
spectively. Amongwomen categorized as normal weight, the
optimal gestationalweight gain rangewas 10.0 kg to less than
18.0kg (ORsat theouter endsof this range,0.96 [95%CI,0.93-
0.99] and0.91 [95%CI, 0.88-0.95]; ARRs,0.01% [95%CI, 0%-
0.01%]and0.02%[95%CI,0.01%-0.03%]).Amongwomencat-
egorized as overweight, the optimal gestational weight gain
rangewas 2.0 kg to less than 16.0 kg (ORs at the outer ends of
this range, 0.81 [95% CI, 0.69-0.95] and 0.90 [95% CI, 0.85-
0.96]; ARRs, 0.05% [95% CI, 0.01%-0.08%] and 0.02% [95%
CI, 0.01%-0.04%]). Among women categorized as obesity
grade 1, the optimal gestational weight gain range was 2.0 kg
to less than 6.0 kg (ORs at the outer ends of this range, 0.76
[95%CI,0.64-0.91] and0.73 [95%CI,0.64-0.84];ARRs,0.07%
[95% CI, 0.02%-0.11%] and 0.08% [95% CI, 0.04%-0.11%]).
Amongwomencategorizedasobesitygrade2, theoptimalges-
tational weight gain range was weight loss or gain of 0 kg to
less than 4.0 kg (median weight loss: 3.0 kg; ORs at the outer
ends of this range, 0.55 [95%CI, 0.39-0.78] and0.67 [95%CI,
0.51-0.88]; ARRs, 0.14% [95% CI, 0.06%-0.22%] and 0.10%
[95% CI, 0.03%-0.17%]). Among women categorized as obe-
sitygrade3, theoptimal gestationalweightgain rangewas0kg
to less than 6.0 kg (ORs for the outer ends of this range, 0.59
[95%CI,0.41-0.85] and0.62 [95%CI,0.41-0.94];ARRs,0.12%
[95%CI, 0.03%-0.21%] and 0.10% [95%CI, 0%-0.20%]). The
ORs and ARRs for each gestational weight gain category used
todeterminetheoptimal rangesappear ineTable8andeTable9
in the Supplement, respectively.
Thegestationalweightgainrangesdefined inthisstudyand
theNAMrangesappear ineTable10 intheSupplement.Theges-
tational weight gain ranges in this studywere roughly compa-
rablewiththeNAMranges forunderweight,normalweight,and
overweight, and were lower for all obesity grades. This study
classified11.3%ofwomen(n = 22236) inthemainsampleashav-
ing inadequate gestational weight gain and 33.8% of women
(n = 66463) as having excessive gestational weight gain. The
NAMcategories classified 21.5%ofwomen (n = 42323) as hav-
ing inadequate gestational weight gain and 42.0% of women
(n = 82544) as having excessive gestational weight gain. Ges-
tationalweight gain outside the ranges from the current study
and the NAM ranges was associated with adverse outcomes
(eFigure 2 and eFigure 3 in the Supplement). Each classifica-
tion system had a low to moderate ability to distinguish be-
tween thosewith and thosewithout adverse outcomes (range
for AUROC, 0.55-0.77; eFigure 4 in the Supplement).
Sensitivity Analyses
Thesensitivityanalyses, inwhichoptimalgestationalweightgain
wasdeterminedbasedonprotective associations regardless of
statisticalsignificance, resultedinbroaderrangesofoptimalges-
tational weight gain (eFigure 5 in the Supplement). Optimal
gestational weight gain ranges similar to those from the main
analyseswereobservedwhenlengthofgestationwasconsidered
and when participants with missing individual outcome data
wereexcluded(eTable11 intheSupplement). Inaddition,thesen-
sitivityanalysesshowedthatoptimalweightgaindefinitionswere
notalteredbyincludingorexcludingpretermbirth,cesareande-
livery,childhoodunderweightoroverweight,gestationaldiabe-
tes, and preeclampsia as adverse outcomes or by adjusting for
maternal age and parity (eTable 11 in the Supplement).
Of all the women classified as having excessive gesta-
tionalweight gainduring the full pregnancy,84.6%alsowould
be classified as having excessive weight gain during the first
half of the pregnancy (eFigure 6, eTable 12, and eTable 13 in
theSupplement).Results for thevalidationsampleshowedthat
the discriminative performance of the optimal gestational
weightgain rangesdeveloped in this studyand theweightgain
ranges from the NAM guidelines were consistent with find-
ings in the main study sample (range for AUROC, 0.50-0.79;
eTable 14, eFigure 7, and eFigure 8 in the Supplement).
Discussion
Maternal prepregnancy BMI, and to a lesser extent gestational
weightgain,areassociatedwithrisksofadversematernalandin-
fantadverseoutcomes.Gestationalweightgainrangesthatwere
associatedwith lowerrisks foradverseoutcomeswere14.0kgto
less than 16.0 kg forwomen categorized as beingunderweight;
10.0kg to less than18.0kg fornormalweight;2.0kg to less than
16.0kgforoverweight;2.0kgtolessthan6.0kgforobesitygrade1;
weight lossorgainof0kg to less than4.0kg forobesitygrade2;
andweight gain of 0 kg to less than 6.0 kg for obesity grade 3.
Gestational weight gain outside these ranges was associ-
atedwith adverse outcomes.However, discriminative perfor-
mance of gestational weight gain with adverse maternal and
infant outcomeswas low tomoderate. PrepregnancyBMIwas
morestronglyassociatedwithadversematernaland infantout-
comes than the amount of gestational weight gain.
Prepregnancy BMI is significantly associated with preg-
nancy complications and offspring obesity and also is associ-
ated with gestational weight gain.5,6 Results from this study
suggest that maternal prepregnancy BMI was more strongly
associated with adverse maternal and infant outcomes than
gestationalweight gain. Therefore, prepregnancyBMImaybe
an important focus for preconception counseling.
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Previous studies that attempted to define optimal gesta-
tionalweight gain associatedwith fewer adverseoutcomesdif-
fered considerably among study populations, statistical
approaches, outcomes, andconclusions regardingoptimal ges-
tationalweight gain ranges.14,16-22Only 1 studyof 120251obese
US women defined optimal gestational weight gain ranges
Figure 3. Associations of GestationalWeight Gain CategoriesWith Any Adverse Outcome
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OR indicates odds ratio and it reflects the risk for any adverse outcome per
gestational weight gain category for womenwith underweight, normal weight,
overweight, obesity grade 1, obesity grade 2, and obesity grade 3, parts A-F,
respectively, comparedwith all other gestational weight gain categories in that
specific group for clinical maternal bodymass index (BMI; calculated asweight in
kilograms divided by height inmeters squared). The solid circles represent theOR
for all participants in each gestational weight gain category. The error bars
indicate 95%CIs. The blue area represents the optimal gestational weight gain
range according to the current analysis, the gray area represents the gestational
weight gain ranges recommended by the USNational Academy ofMedicine
(NAM; formerly the Institute ofMedicine). The gestational weight gain categories
were 2 kg each. Participants in the extreme categories of gestational weight gain
had values beyond themost extreme labeled tickmarks. Thematernal BMI
categories were underweight (<18.5), normal weight (18.5-24.9), overweight
(25.0-29.9), obesity grade 1 (30.0-34.9), obesity grade 2 (35.0-39.9), and obesity
grade 3 (40.0). Any adverse outcome includes preeclampsia (gestational
hypertension plus proteinuria), gestational hypertension (systolic blood pressure
140mmHg, diastolic blood pressure90mmHg, or both after 20weeks of
gestation in previously normotensivewomen), gestational diabetes (a random
glucose level >11.0mmol/L, a fasting glucose level7.0mmol/L, or a fasting
glucose level between 6.1 and 6.9mmol/Lwith a subsequent abnormal glucose
tolerance test [glucose level >7.8mmol/L after glucose intake]), cesarean delivery,
preterm birth (gestational age at birth <37weeks), and small or large size for
gestational age at birth (sex- and gestational age–adjusted birthweight <10th
percentile and >90th percentile, respectively). For the gestational weight gain
ranges defined in this study, a statistically significant OR lower than 1 for a
gestational weight gain categorywas considered the optimal weight gain. If a
nonsignificant association (either with anOR >1, <1, or of 1) for a gestational weight
gain categorywas surrounded by 2 significant estimateswith anOR below 1, that
gestational weight gain categorywas included in the optimal gestational weight
gain range. The number of cases for each outcome and the total number of
participants in each gestational weight gain category appear in eTable 7 in the
Supplement. The optimal gestational weight gain ranges based only on protective
associations appear in eFigure 5 in the Supplement.
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according to maternal obesity grade 1 (4.5 kg-11.3 kg), obesity
grade2 (0kg-4.1kg), andobesitygrade3 (weight loss<4kg),and
that study used data from term births only.21
Compared with prior work, the present study focused on
commonandimportantadversematernaland infantoutcomes,
includedwomenfrommultipleWesterncountries,andcompared
theassociationsofgestationalweightgainandprepregnancyBMI
withadverseoutcomes.ConsistentwiththeNAMguidelines,this
studyusedtotal gestationalweightgain to identifyoptimalges-
tationalweightgainranges insteadofgestationalweightgainper
week because gestational weight gain does not have a linear
pattern.7,8Total gestationalweightgain isdependent inparton
pregnancyduration.Theobservedresultsweresimilarafterad-
justment forgestationalageatbirthandafterexcludingpreterm
births.Consistentwith theNAMguidelines, this study showed
that amongwomenwith higher prepregnancy BMI, lower ges-
tationalweightgainwasassociatedwithfeweradverseoutcomes.
Gestational weight gain ranges for women categorized as obe-
sitygrade1,2,or3were lowerthantheNAMguidelinesandeven
involvedweight loss for severely obese women, although nei-
therclassificationwaspredictiveforadverseoutcomes.However,
theresults forseverelyobesewomenshouldbe interpretedwith
caution because the optimal gestational weight gain ranges
for obesity grades 1 through 3 associatedwith better outcomes
fluctuate and do not follow a clear linear trend. These results
may represent the relatively small sample sizeofobesewomen
and lack of statistical power rather than biological plausibility.
Future studies should evaluate the effect and safety of weight
loss during pregnancy in severely obesewomen.
Gestationalweightgainguidelinesareused inseveralWest-
ern countries for preconception counseling. The gestational
weight gain ranges developed in this study classified fewer
women as having suboptimal weight gain comparedwith the
NAMguidelines.However, thediscriminativeperformance, as
indicated by theAUROC,wasweak for both classification sys-
tems. This suggests that the use of gestational weight gain
guidelinesmayneed to be reconsidered for individual predic-
tion of the risk for adverse outcomes. Future research should
assess whether optimal gestational weight gain ranges com-
bined with other maternal and fetal pregnancy characteris-
tics are useful for prediction of adverse outcomes.
The findings from this study suggest that prepregnancy
weightmightbeamore important target for interventions than
gestational weight gain. Previous studies of dietary and physi-
cal activity interventions for pregnantwomen have not shown
an effect on pregnancy outcomes.23-26 Based on current evi-
dence, future clinical trials designed to reduce weight-related
maternal and infant adverse outcomes should focus onmater-
nal weight before or at the start of pregnancy.
Limitations
This studyhas several limitations. First, not all invited cohorts
wereabletoparticipateinthecurrentanalyses.Second,theanaly-
ses did not measure changes in the association of gestational
weight gainwith adverseoutcomesover time.The resultsmay
be biased if the association of gestational weight gainwith ad-
verseoutcomeschangedovertime.Third,dataonprepregnancy
weight wasmainly self-reported, and the latest weight during
pregnancywaseither self-reportedormeasured.Thismayhave
led tomisclassification of gestational weight gain. Fourth, the
composite outcome of any adverse outcomemight have been
misclassifiedasa resultof somemissingdata for individualout-
comes. Fifth, all outcomeswere considered equally important
andtheanalysesdidnotaccount for thedifferences inoutcome
severity.Sixth,cesareandeliverymaybeduetomanyfactorsand
maynotbeanappropriateoutcomefor studyingassociationsof
weight changewith adversematernal outcomes.7 Seventh, in-
formationonstillbirthwasnotavailable.Eighth,optimalgesta-
tionalweight gainwasdefined as a protective associationwith
theriskforanyadverseoutcome,reflectingthebestoutcomepos-
sible and limiting thenumberofparticipants incorrectly classi-
fiedashavingadequategestationalweightgain.Therangeswould
beslightlybroader ifoptimalgestationalweightgainwasdefined
asno increased risk for adverseoutcomes,which includesboth
aprotectiveassociationandanull association.Ninth, theanaly-
seswere not adjusted formultiple testing. Tenth, as a result of
the limited sample sizes for underweight and severely obese
women,heterogeneitywasnotassessed.Eleventh,basedonthe
profilesofall the includedcohorts, about 1%ofwomenwere in-
cluded more than once for multiple pregnancies. Twelfth, for
some outcomes, discriminative performance in the validation
sample was lower than in themain sample, potentially result-
ing fromoverfitting of themodels in themain sample.
Conclusions
In thismeta-analysisofpooled individualparticipantdata from
25cohort studies, the risk for adversematernal and infantout-
comes varied by gestational weight gain and across the range
of prepregnancy weights. The estimates of optimal gesta-
tional weight gainmay inform prenatal counseling; however,
the optimal gestational weight gain ranges had limited pre-
dictive value for the outcomes assessed.
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Editor's Note
PrepregnancyBodyMass Index,WeightGainDuringPregnancy,
andHealthOutcomes
MaryM. McDermott, MD; Linda Brubaker, MD
Each year, approximately 130million infants are bornworld-
wide, and therewere 3.8million births in theUnited States in
2017.1 Rates ofmaternalmortality andadversepregnancyout-
comes in theUnitedStatesare
increasing, and abnormal
prepregnancy body mass in-
dex (BMI) andabnormal gestationalweight gainhavebeenas-
sociated with these adverse outcomes.
In a recent meta-analysis published in JAMA, Goldstein
et al2 reported that gestational weight gain exceeded weight
gain recommended by the Institute ofMedicine (now theNa-
tional Academy of Medicine) in 47% of 1 309 136 pregnan-
cies. Women with excess gestational weight gain were more
likely toundergo cesareandelivery (odds ratio [OR], 1.30 [95%
CI, 1.25-1.35]; absolutedifference: 4%) andmore likely tohave
infants who were large for gestational age (OR, 1.85 [95% CI,
1.76-1.95]; absolutedifference:4%)orwhometcriteria formac-
rosomia (OR, 1.95 [95%CI, 1.79-2.11]; absolutedifference:6%).2
In this issueof JAMA, theLifeCycle Project-MaternalObe-
sity and Childhood Outcomes Study Group3 reports the re-
sults of an individual patient-levelmeta-analysis inwhich the
amount of gestational weight gain associated with fewer ad-
verse pregnancyoutcomeswasdefined according to prepreg-
nancy BMI. Even though the amount of optimal weight gain
duringpregnancyvaried according toprepregnancyBMI, ges-
tational weight gain had only low tomoderate discriminative
performance for adverse outcomes.
In contrast, prepregnancy BMI values above normalwere
strongly associated with higher rates of adverse outcomes.
These associationswereobserved regardless of the amount of
gestationalweight gain. Thus, an important conclusionof the
report by Voerman et al3 is that prepregnancy BMI was more
strongly associated with adverse maternal and infant out-
comes than the amount of gestational weight gain.
Obesity affects 40% of women in the United States.4
Ensuring that pregnancies result in healthy mothers and
infants is an important public health goal. Based on the study
by Voerman et al,3 resources should be dedicated toward
ensuring an optimal BMI for all women of reproductive age
rather than on gestational weight gain.5 Recent guidelines
and available services can help achieve this important public
health goal.5,6
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